billHR3419Event Wednesday, April 22, 2026Analyzed

To amend the Public Health Service Act to reauthorize the telehealth network and telehealth resource centers grant programs.

Neutral
Impact2/10

Summary

HR3419, a bill to reauthorize telehealth network and resource center grant programs, has been referred to the Senate Committee on Health, Education, Labor, and Pensions. This early-stage legislative action indicates continued congressional interest in telehealth infrastructure, but no immediate market impact is expected as it is an authorization bill and has not yet advanced through the legislative process.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR3419 is an early-stage authorization bill focused on reauthorizing existing telehealth grant programs.
  • 2.The bill does not allocate funding; actual appropriations would be required in separate legislation.
  • 3.No immediate market impact is anticipated due to the bill's early legislative stage and authorization nature.

Market Implications

As an early-stage authorization bill, HR3419 currently has a neutral market implication. It signals continued legislative support for telehealth infrastructure, which could benefit companies in the Healthcare and Technology sectors involved in telehealth services and platforms. However, without specific funding allocations or a clearer path to passage, there is no direct or immediate impact on specific tickers. The reauthorization of these programs would primarily maintain the existing market structure for telehealth support services rather than creating new demand.

Full Analysis

HR3419, titled "To amend the Public Health Service Act to reauthorize the telehealth network and telehealth resource centers grant programs," was received in the Senate and read twice before being referred to the Committee on Health, Education, Labor, and Pensions on April 22, 2026. This places the bill in an early stage of the legislative process within the 119th Congress. The bill's current status as "Referred to committee" means it is undergoing review and potential amendment by the Senate committee. As an authorization bill, HR3419 would set policy and spending ceilings for telehealth programs but would not allocate actual funds. Any funding for these reauthorized programs would require a separate appropriations bill. Therefore, there is no direct funding amount associated with this bill at its current stage. Structural beneficiaries of such legislation, if it were to advance and be funded, would include companies providing telehealth platforms, remote monitoring devices, and secure communication technologies. However, without specific funding mechanisms or appropriations, it is premature to identify specific companies as direct winners. The bill's focus on reauthorization suggests a continuation of existing programs rather than the creation of new market opportunities. The recent Executive Order on "Accelerating Medical Treatments for Serious Mental Illness" is not directly relevant to this telehealth reauthorization bill, as the EO focuses on psychedelic-based therapies and regulatory acceleration, while HR3419 addresses general telehealth infrastructure. For HR3419 to become law, it must pass through the Senate committee, be voted on by the full Senate, and then potentially reconciled with any House version before being sent to the President for signature. Given its early stage, the timeline for potential passage is uncertain and likely extends several months.

Market Impact Score

2/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.